Press Release
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication.
Impressive phase III trial data in AD
Its Priority Review is expected to accelerate its NDA approval
Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas.
Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.
- Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).
- Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.
Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.
Building an integrated AD solution,
strengthening Dermavon’s leadership in dermatology
AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.
Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.
Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health.
More Information About Ruxolitinib Phosphate Cream
Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].
The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).
Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference:
1. China Insights Consultancy’s industrial report
2. The U.S. FDA approval information can be found on the Incyte official website, as follows:
3. The EMA approval information can be found on the Incyte official website, as follows:
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Cafe Solutions Expands Seating Range with Modern Metal Chairs for Cafes and Restaurants
Brendale 4500, Queensland, Australia, 16th Mar 2026 – Cafe Solutions, a supplier of commercial café and restaurant furniture across Australia, has expanded its seating range with the introduction of modern metal chairs designed for hospitality venues. The development reflects ongoing demand within the hospitality sector for durable metal chairs suited to high-traffic dining environments.
Hospitality venues across Australia regularly review seating arrangements and interior layouts to accommodate operational requirements and evolving customer expectations. Chairs remain an essential component of venue design, influencing both seating capacity and the organisation of dining areas. As cafés and restaurants continue to adapt to changing service patterns, furniture choices increasingly prioritise durability, practicality, and compatibility with different interior styles.
Cafe Solutions reported that the expanded range of metal chairs has been developed to support hospitality businesses seeking seating suitable for consistent use in commercial environments. Metal chairs are commonly selected for hospitality settings due to their structural stability and ability to withstand daily wear associated with busy service periods.
Russell Crawford, spokesperson for Cafe Solutions, said the expanded seating range reflects practical considerations frequently raised by hospitality operators.
“Hospitality venues require seating that maintains reliability during daily service while fitting comfortably within different dining environments,” Crawford said. “The introduction of modern metal chairs reflects the importance of durable materials and stable construction for cafés and restaurants operating in busy commercial settings.”
Across the hospitality industry, furniture selection plays an important role in shaping the functionality of a venue. Dining layouts must accommodate customer flow, staff movement, and efficient use of available floor space. Seating options that remain sturdy while also being easy to reposition are often preferred in environments where layouts may be adjusted throughout the day.
Metal chairs have long been used in commercial hospitality settings because of their resilience under frequent use. Materials such as powder-coated steel and reinforced frames are commonly chosen for their ability to resist wear and maintain structural integrity over time. These characteristics allow hospitality venues to maintain consistent seating arrangements without frequent replacement.
Cafe Solutions supplies furniture to hospitality businesses throughout Australia, including cafés, restaurants, bars, hotels, and other food service establishments. The company’s catalogue includes a wide range of commercial furniture such as chairs, tables, bar stools, benches, and stainless steel sinks designed for professional hospitality environments.
The introduction of modern metal chairs forms part of a broader response to industry trends in furniture design and venue layout. Hospitality operators often seek furniture capable of integrating into a variety of interior styles, from contemporary café spaces to more traditional restaurant settings. Seating designs, therefore, often focus on materials and forms that complement different hospitality environments.
Operational practicality remains an important consideration for seating used in commercial venues. Metal chairs in hospitality environments are frequently moved, stacked, or rearranged during daily service. Furniture designed for these conditions supports efficient space management during busy service periods and assists venues in preparing for different seating arrangements.
Outdoor dining areas have also become increasingly common across many regions of Australia. Seating used in outdoor hospitality spaces must withstand exposure to weather while maintaining structural durability. Metal chairs are frequently used in these areas because of their resistance to environmental conditions and straightforward maintenance.
Cafe Solutions distributes furniture from its facility in Brendale, Queensland, with shipping available across Australia. Reliable delivery and consistent product availability remain important considerations for hospitality businesses undertaking venue renovations, refurbishments, or new openings.
Crawford noted that ongoing developments within the hospitality sector continue to influence how furniture suppliers approach future product planning.
“The hospitality sector continues to evolve as venues adjust layouts and seating arrangements to reflect changing dining patterns,” Crawford said. “Future developments will focus on metal chairs and other furniture designs that support adaptable hospitality spaces and long-term reliability for cafés and restaurants throughout Australia.”
Cafe Solutions operates from its headquarters at 12 Kingsbury St, Brendale QLD 4500, and supplies commercial furniture nationwide to hospitality venues seeking furnishings suited to professional environments.
For further information about metal chairs, contact Cafe Solutions at (07) 3184 8441 or via email at sales@cafesolutions.com.au
Media Contact
Organization: Cafe Solutions
Contact Person: Russell Crawford
Website: https://cafesolutions.com.au/
Email: Send Email
Contact Number: +61731848441
Address:12 Kingsbury St
City: Brendale 4500
State: Queensland
Country:Australia
Release id:42689
The post Cafe Solutions Expands Seating Range with Modern Metal Chairs for Cafes and Restaurants appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Brendale 4500, Queensland, Australia, 16th Mar 2026 – Cafe Solutions, a leading supplier of commercial cafe and restaurant furniture across Australia, has announced the expansion of its commercial bar stool range designed to support the practical demands of hospitality venues. The development reflects increasing interest among cafes, restaurants, and bars seeking furniture capable of withstanding frequent use while maintaining a consistent appearance within hospitality settings.
Hospitality businesses frequently rely on bar stools to create functional seating arrangements at counters, bar areas, and high tables. These seating options allow venues to optimise available space while supporting relaxed dining environments. As hospitality venues experience steady customer traffic, seating durability and stability have become important factors in furniture selection.
Cafe Solutions has broadened its bar stool collection to address these operational requirements. The expanded range includes stools manufactured from materials such as reinforced metal, treated timber, and weather-resistant components suitable for both indoor and outdoor hospitality environments. Designs focus on structural strength and reliability while maintaining compatibility with a variety of venue layouts and interior styles.
Russell Crawford, spokesperson for Cafe Solutions, stated that the expanded range reflects ongoing discussions with hospitality operators regarding furniture performance and longevity.
“Hospitality venues require seating capable of maintaining structural integrity under constant use while preserving a professional appearance,” Crawford said. “The commercial bar stool range has been expanded to address practical requirements such as durability, stability, and materials appropriate for both indoor and outdoor hospitality environments.”
Across Australia, the hospitality sector continues to evolve as venues adapt to changing customer expectations and operational needs. Renovations, venue upgrades, and new cafe openings have contributed to increased attention on furniture choices that support efficient space planning and long-term usability.
Bar stools remain a common feature in modern hospitality layouts. Counter seating and bar-style dining arrangements allow venues to accommodate additional patrons while creating flexible dining areas. As a result, hospitality operators often seek seating options designed to withstand high customer turnover without requiring frequent replacement.
Cafe Solutions supplies furniture to cafes, restaurants, bars, hotels, and other food service establishments throughout Australia. The company’s catalogue includes a broad range of commercial furniture such as chairs, tables, benches, and stainless steel sinks designed for professional hospitality environments.
The expanded bar stool range was developed with operational practicality in mind. Many hospitality venues require seating that can be repositioned easily during daily service while remaining stable and secure during use. Materials selected for commercial furniture must also tolerate regular cleaning and exposure to environmental conditions, particularly in outdoor dining areas.
Outdoor hospitality spaces have become increasingly common across many regions of Australia, particularly in areas with favourable climates. Seating designed for outdoor use must resist weather exposure while maintaining structural durability. The expanded collection includes bar stools suitable for these conditions, allowing venues to maintain consistent seating styles across indoor and outdoor areas.
In addition to product development, Cafe Solutions continues to focus on logistics and nationwide distribution. Hospitality businesses often operate within strict timelines for renovations, relocations, and venue openings, creating a need for reliable delivery of commercial furniture across different regions of Australia.
Crawford noted that continuing changes within the hospitality sector influence how furniture suppliers approach future product development and availability.
“The hospitality sector continues to adapt to evolving dining habits and venue layouts,” Crawford said. “Future developments within commercial furniture will focus on long-term durability, adaptable designs, and dependable supply to support hospitality venues throughout Australia.”
Cafe Solutions operates from its headquarters at 12 Kingsbury St, Brendale QLD 4500. The company distributes commercial furniture products across Australia, providing seating and furnishings designed specifically for hospitality environments.
For further information about commercial bar stools, contact Cafe Solutions at (07) 3184 8441 or via email at sales@cafesolutions.com.au.
Media Contact
Organization: Cafe Solutions
Contact Person: Russell Crawford
Website: https://cafesolutions.com.au/
Email: Send Email
Contact Number: +61731848441
Address:12 Kingsbury St
City: Brendale 4500
State: Queensland
Country:Australia
Release id:42688
The post Cafe Solutions Enhances Hospitality Spaces with Durable Commercial Bar Stools appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
The petrochemical complex of the Petromidia Refinery, part of the KMG International Group, has begun producing polypropylene copolymer following the modernization of its polypropylene unit.
The upgrade enabled the facility to introduce new polymer grades and expand its portfolio of higher-value-added petrochemical products.
During production trials conducted in February, the unit produced around 187 tons of copolymer, including the licensed grade J730 and the newly developed grade RRCP25. The tests confirmed the material’s stable operation and compliance with end-user requirements.
The unit’s maximum capacity for copolymer production is 140-144 tons per day, enabling the complex to increase output of higher-value polymer products.
After the refinery completes scheduled maintenance and restarts the unit in April, the company plans to begin regular copolymer production, targeting more profitable polymer market segments and growing regional demand.
Polypropylene copolymers offer improved impact resistance, flexibility, and low-temperature performance compared to conventional polypropylene. These properties make them suitable for industrial packaging, logistics containers, large plastic crates, and automotive components.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Cafe Solutions Expands Seating Range with Modern Metal Chairs for Cafes and Restaurants
Cafe Solutions Enhances Hospitality Spaces with Durable Commercial Bar Stools
Petromidia Refinery Launches Production of Premium Polymer Grade
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release3 days ago
ForexBrokers.Live: Simplifying MT4 and MT5 for Forex Traders
-
Press Release4 days ago
Brian Hagerty Brings Proven Service Industry Leadership and Operational Expertise to Next Chapter
-
Press Release5 days ago
Post Oak Group Expands Its Capital Markets Practice Into European Markets
-
Press Release2 days ago
European Scientologists Expand Human Rights Education in Europe and Abroad
-
Press Release6 days ago
HumaTek Officially Lists $HUMC Token on PancakeSwap, Expanding Humanitarian Presence Across the Blockchain
-
Press Release4 days ago
Somos Martina Launches Period Uniform Program, Integrating Period Underwear into Colombian School Uniform System
-
Press Release4 days ago
A Mathematician’s Perspective: The MatrixFlow Model Behind Feather Exchange
-
Press Release5 days ago
Yijin Solution Optimizes Multi-Axis Manufacturing with Next-Generation 5-Axis CNC Machining